Placebo response is influenced by the pain syndrome evaluated. These differences should be considered when evaluating novel compounds for the treatment of neuropathic pain conditions.
Chronic renal failure (CRF) is commonly associated with various adverse consequences including pathological vascular calcification (VC), which represents a significant clinical concern. Existing literature has suggested the involvement of histone deacetylases (HDACs) in the progression of CRF‐induced VC. However, the underlying molecular mechanisms associated with HDACs remain largely unknown. Therefore, we established the adenine‐induced CRF rat model and in vitro VC models based on vascular smooth muscle cells (VSMCs) to examine HDAC1/lysine demethylase 1A (LSD1)/SESN2 as a novel molecular pathway in CRF‐induced VC. Our initial results demonstrated that HDAC1 reduced the formation of VC in vivo and in vitro. HDAC1 was found to deacetylate LSD1, which subsequently led to impaired transcriptional activity in CRF‐induced VC. Moreover, our results illustrated that LSD1 diminished the enrichment of H3K4me2 at the SESN2 promoter. Autophagy was identified as a vasculo‐protective element against calcification in VC. Finally, we found that the inhibitory effects of HDAC1 overexpression on VC were partially abolished via over‐expressed LSD1 in adenine‐induced CRF model rats and in high phosphate‐induced VSMCs. Taken together, these results highlight the crucial role of HDAC1 as an antagonistic factor in the progression of VC in CRF, and also revealed a novel regulatory mechanism by which HDAC1 operates. These findings provide significant insight and a fresh perspective into promising novel treatment strategies by up‐regulating HDAC1 in CRF.
Cyclophosphamide (CTX) is one of the most commonly used alkylating agents for the treatment of various cancers; however, CTX‐induced nephrotoxicity is one of the most prevailing side effects of the drug. Shorea roxburghii is a plant with diverse bioactivities including antioxidant, anti‐inflammatory and renoprotective effects. This study investigated the nephroprotective effect of Shorea roxburghii phenolic extract (SRPF) against CTX‐induced nephrotoxicity in rats. The rats were treated with SRPF (100 and 400 mg/kg) for 5 weeks and were concomitantly administered with CTX. The results indicated that treatment with SRPF significantly decreased serum creatinine, blood urea nitrogen (BUN), uric acid as well as renal MDA, IL‐6, TNF‐α, IL‐1β, NF‐kB and caspase‐3 levels. Furthermore, SRPF augmented the activities of renal SOD, CAT, GSH and GPx. SRPF also improved renal histopathological damages caused by CTX administration. In conclusion, these results suggested that SRPF showed substantial protective effects against CTX‐mediated renal toxicity via its antioxidant and anti‐inflammatory effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.